Neuroimaging studies using dopamine transporter (DAT) ligands have consistently shown that during the early symptomatic stages of PD, the degeneration of dopamine release sites and axonal terminals is more pronounced than that of the cell bodies and proximal axons [7,8]. This evidence concerns the gene SLC6A3 and Parkinson disease.